Skip to main content

Boundless Bio, Inc.

For the period ended Jun 30, 2026. Filed Aug 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 7, 2026

BOLD$2.46+2.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except par value data)

June 30,December 31,
20262025
(unaudited)
Assets
Current assets
Cash and cash equivalents$20,213$17,868
Short-term investments52,41389,713
Prepaid expenses and other current assets1,0212,030
Total current assets73,647109,611
Property and equipment, net973,216
Right-of-use asset, net—43,659
Restricted cash—560
Other assets—13
Total assets$73,744$157,059
Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued liabilities$4,995$6,727
Accrued compensation2,7732,643
Lease liabilities, current portion—3,167
Total current liabilities7,76812,537
Lease liabilities, non-current—45,868
Total liabilities7,76858,405
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 70,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025——
Common stock, $0.0001 par value; 700,000 shares authorized, 22,475 shares issued and outstanding as of June 30, 2026; 700,000 shares authorized, 22,407 shares issued and outstanding as of December 31, 202522
Additional paid-in-capital362,923358,257
Accumulated other comprehensive income (loss)(32)64
Accumulated deficit(296,917)(259,669)
Total stockholders’ equity65,97698,654
Total liabilities and stockholders’ equity$73,744$157,059
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.